Literature DB >> 3497285

Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.

Y Morikawa, S Watanabe, T Kodama.   

Abstract

The cytotoxic activities, of the peripheral blood lymphocytes (PBL) and regional lymph node lymphocytes (LNL) generated by incubation with recombinant IL-2 (rIL-2) in vitro, have been studied to assess their effects on autologous pulmonary adenocarcinoma cells from 21 patients with lung cancer. The lymphokine-activated killer (LAK) activities of PBL were 22.9 +/- 14.8% for autologous pulmonary adenocarcinoma cells and 44.9 +/- 20% for PC-9 cells. A previous coculture of autologous tumor cells with PBL (ATS-LAK) showed no increase in induction of cytotoxicity to autologous tumor cells. The LAK activities of LNL were significantly lower than those of PBL. The cytotoxicities of rIL-2 activated lymphocytes seemed lower in well differentiated pulmonary adenocarcinoma than in moderately and poorly differentiated adenocarcinoma, and higher in patients with lymph node metastasis than in those without; they appeared, however, not to be related to clinical stage or degree of infiltration of T-zone histiocytes into the cancer stroma. The cytotoxicity to autologous tumor cells was not significantly different in the presence of the Ia antigen expressed on tumor cells, but the cytotoxicity to Ia positive PC-9 cells was significantly higher for rIL-2 activated lymphocytes from patients with lung cancer cells which were Ia positive than from those where they were Ia negative. The presence of Ia antigen on tumor cells seemed important for antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497285

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  1 in total

1.  Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.

Authors:  N Rajaram; R J Tatake; S H Advani; S L Naik; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.